ZEVRA THERAPEUTICS, INC.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
ZVRA$12.14+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 6. EXHIBITS
The following is a list of exhibits filed as part of this Form 10-Q (the SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q, and 8-K is 001-36913):
| Exhibit No. | Description |
| 3.1 | Restated Certificate of Incorporation of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrant’s Annual Report on Form 10-K as filed with the SEC on March 9, 2026). |
| 3.2 | Amended and Restated Bylaws, as currently in effect, of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrant's Current Report on Form 8-K as filed with the SEC on February 28, 2024). |
| 4.1 | Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to the Registrant's Annual Report on Form 10-K as filed with the SEC on March 12, 2021). |
| 10.1*+# | Asset Purchase and Settlement Agreement, dated March 13, 2026, by and between Zevra Therapeutics, Inc. and Commave Therapeutics SA. |
| 10.2! | Employment Agreement, effective as of March 9, 2026, by and between Zevra Therapeutics, Inc. and Justin Renz (incorporated by reference to the Registrant's Current Report on Form 8-K as filed with the SEC on March 9, 2026). |
| 10.3*+# | Lease, effective as of March 31, 2026, by and between 75-101 Fed Owner, L.L.C. and Zevra Therapeutics, Inc. |
| 10.4*! | First Amendment, dated January 29, 2026, to the Employment Agreement, dated October 10, 2023, as amended, by and between Neil McFarlane and Zevra Therapeutics, Inc. |
| 10.5*! | First Amendment, dated January 29, 2026, to the Employment Agreement, dated January 23, 2024, by and between Adrian Quartel and Zevra Therapeutics, Inc. |
| 10.6*! | First Amendment, dated January 29, 2026, to the Employment Agreement, dated January 6, 2023, by and between Joshua Schafer and Zevra Therapeutics, Inc. |
| 10.7*! | First Amendment, dated January 29, 2026, to the Employment Agreement, dated June 20, 2024, by and between Rahsaan Thompson and Zevra Therapeutics, Inc. |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. |
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. |
| 32.1** | Certification of the Principal Executive Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of the Principal Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS* | Inline XBRL Instance Document |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104** | Cover page Interactive Data File (embedded within the Inline XBRL and combined in Exhibit 101) |
| * | Filed herewith |
|---|---|
| ** | Furnished herewith |
| ! | Management contract or compensatory plan |
| + | Certain portions of the exhibit, identified by the mark, “[***]”, have been omitted because such portions contained information that is both (i) not material and (ii) the type that the Company treats as private or confidential |
| # | Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the Securities and Exchange Commission upon request; provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.